OncoMatch/Clinical Trials/NCT06343402
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Is NCT06343402 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including BBO-8520 and Pembrolizumab for non-small cell lung cancer.
Treatment: BBO-8520 · Pembrolizumab · BBO-10203 — A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a KRAS (Kirsten rat sarcoma) G12C mutation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: KRAS g12c mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- O'Neal Comprehensive Cancer Center at UAB · Birmingham, Alabama
- University of California - San Diego Moores Cancer Center · La Jolla, California
- University of California San Francisco · San Francisco, California
- UCLA Health - Santa Monica Cancer Care · Santa Monica, California
- University of Colorado Cancer Center · Aurora, Colorado
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify